Leveraging Viruses as Precision Therapeutic Agents
contact us at dd.mvb@theralytics-inc.com
Leveraging Viruses as Precision Therapeutic Agents
contact us at dd.mvb@theralytics-inc.com
About THERALYTICS Inc
Innovative Therapy
At THERALYTICS Inc, we are pioneering a novel theralytic virus, EVIREXA™ that selectively targets and replicates in cancer and certain virally infected cells leading to host immune engagement and activation culminating in immune clearance of local and distant lesions.
About THERALYTICS INC
EVIREXA™
Our Mission
Our Mission
THERALYTICS Inc is developing EVIREXA™, a first-in-class, patented oncolytic Human Rhinovirus (common cold virus) that has the ability to replicate and kill multiple cancer and virally infected human cells, but remains unable to harm normal cells.
Our Mission
Our Mission
Our Mission
THERALYTICS Inc is dedicated to harnessing the therapeutic potential of human rhinoviruses to develop transformative immunotherapies that eliminate cancer and virus-induced disease while establishing durable, systemic immune protection.